Stem Cell Therapy for Crohn's Disease: What Patients Should Know

Stem cell therapy has become one of the most talked-about frontiers in Crohn's disease research, and for good reason. For those of us living with refractory disease - where biologics and other advanced therapies have fallen short - the idea of harnessing the body's own repair system is compelling. But separating genuine science from hype is essential, especially when stem cell therapy for Crohn's disease is increasingly marketed by unregulated clinics. Here is what the evidence actually shows, who might benefit, and what remains uncertain.

Key Takeaways

• A 2024 meta-analysis of 12 randomized controlled trials with 632 patients found stem cell therapy more than doubled the odds of clinical remission versus placebo, with no increase in serious adverse events (1)
• Darvadstrocel is the only approved stem cell product for Crohn's-related perianal fistulas, currently available in the EU, Israel, and Japan but not in the U.S. (4)
• In a 2025 international study of 68 patients, 65% achieved clinical remission after autologous hematopoietic stem cell transplant, and 46% needed no further advanced therapy (2)
• The ASTIClite trial was halted after serious adverse events including two deaths, highlighting that the conditioning protocol used before transplant is critical for safety (5)
• Patients should be cautious of unregulated commercial stem cell clinics and consult their gastroenterologist about evidence-based options or clinical trials

What Is Stem Cell Therapy for Crohn's Disease?

Stem cell therapy for Crohn's disease involves using specialized cells that can repair damaged tissue or reset a malfunctioning immune system. Researchers are studying two fundamentally different approaches - mesenchymal stem cells (MSCs) that target local tissue repair and hematopoietic stem cells (HSCs) that reboot the entire immune system. Understanding the distinction between these two types is key to evaluating the research.

How Stem Cells Work in the Body

Stem cells are the body's raw materials - cells from which all other specialized cells are generated. In the context of Crohn's disease, two types have drawn the most research attention.

Mesenchymal stem cells (MSCs) are found in bone marrow, fat tissue, and other sources. They can reduce inflammation, promote tissue healing, and modulate the immune response. When injected directly into a damaged area like a fistula tract, MSCs release anti-inflammatory molecules and help rebuild the surrounding tissue.

Hematopoietic stem cells (HSCs) are the precursors to all blood and immune cells. In an HSC transplant, chemotherapy first wipes out the patient's existing immune system, and then reinfused stem cells rebuild it from scratch - ideally without the autoimmune programming that drives Crohn's disease.

Stem cells can come from the patient themselves (autologous) or from a donor (allogeneic). Each source has trade-offs in terms of availability, immune compatibility, and risk.

Why Researchers Are Studying Stem Cells for Crohn's

The rationale is straightforward: Crohn's disease involves an immune system that attacks the gut lining, causing chronic inflammation and tissue damage. MSC therapy aims to calm that response locally and promote healing, while HSCT aims to replace the immune system entirely. Both approaches address the disease at a deeper level than conventional medications, which suppress symptoms without correcting the underlying immune dysfunction.

For patients who have cycled through multiple biologics without lasting relief - and who may be facing repeated surgeries - stem cell approaches represent a fundamentally different strategy.

MSC Therapy for Perianal Fistulas

Perianal fistulas are one of the most painful and difficult-to-treat complications of Crohn's disease, affecting roughly one in three patients over their lifetime. MSC therapy has shown the strongest evidence in this specific application, and it is the only area where a stem cell product has achieved regulatory approval for Crohn's.

How MSC Injection Works

The procedure involves injecting MSCs directly into the tissue surrounding the fistula tract. This is typically done under anesthesia after the fistula has been cleaned and any abscesses drained. The cells are either derived from the patient's own fat tissue or from a donor source.

Researchers at UC Davis discovered that MSCs work through a fascinating two-stage mechanism. First, the stem cells release prostaglandin E2, which suppresses inflammatory T-cells in the surrounding tissue. Then, as the stem cells naturally die off, immune cells consume them through a process called efferocytosis - and this consumption actually reprograms those immune cells into an anti-inflammatory state that sustains the healing effect long after the original stem cells are gone (3).

This explains something that puzzled scientists for years: how a single injection of cells that survive only days or weeks could produce healing that lasts months. The stem cells essentially "teach" the local immune environment to behave differently.

What the Research Shows

The evidence for MSC therapy in perianal fistulas is the most robust of any stem cell application in Crohn's disease. A 2024 meta-analysis pooling data from 12 randomized controlled trials with 632 patients found that stem cell therapy more than doubled the odds of achieving clinical remission compared to placebo (OR 2.08, p less than 0.001), with no increase in serious adverse events (1).

That last point is worth emphasizing: the safety profile of MSC injection for fistulas was comparable to placebo across these trials. For a condition where surgical options carry their own significant risks, a treatment that is both more effective and well tolerated is noteworthy.

Hematopoietic Stem Cell Transplant for Refractory Crohn's

HSCT is a far more intensive procedure than MSC injection, and it is reserved for patients with severe, treatment-refractory Crohn's disease. The goal is ambitious: completely reset the immune system so that it no longer attacks the gut. The evidence is encouraging but comes with important safety caveats.

Who Might Be a Candidate

HSCT is studied specifically for patients who have not responded to multiple biologic therapies - sometimes called "biologic-refractory" Crohn's disease. These are patients who have typically tried and failed anti-TNF drugs, vedolizumab, ustekinumab, and possibly newer agents, and who face the prospect of repeated surgeries or ongoing severe symptoms.

This is not a first-line or even second-line treatment. The intensity of the procedure - which involves chemotherapy conditioning followed by weeks of immune suppression - means it is considered only when the risks of continuing with refractory disease outweigh the risks of transplant.

Efficacy and Safety Evidence

A 2025 international multicenter study followed 68 patients who underwent autologous HSCT for refractory Crohn's disease. The results were striking: 65% achieved clinical remission and 75% showed endoscopic improvement at a median follow-up of 2 years. Perhaps most remarkably, 46% of patients did not need any advanced therapy after HSCT - meaning nearly half were able to stay off biologics entirely (2). The study reported zero cases of bowel failure or long-term transplant complications.

However, the picture is more complex than these encouraging numbers suggest. The ASTIClite randomized trial, which used a different conditioning protocol, showed endoscopic improvement but had to be halted after serious adverse events including renal failure and two patient deaths (5). This trial demonstrated that the specific chemotherapy regimen used to prepare the body for transplant is critical - too aggressive, and the risks become unacceptable; too mild, and the immune reset may not be complete enough to produce lasting remission.

The difference in outcomes between studies highlights an important point: not all HSCT protocols are equal. The conditioning regimen, patient selection criteria, and the experience of the transplant center all significantly influence both the effectiveness and safety of the procedure.

Current Approval Status and Clinical Trials

Understanding what is actually approved versus what is still experimental helps patients navigate conversations with their healthcare teams and avoid being misled by unproven offerings.

What Is Approved and Where

No stem cell therapy is currently FDA-approved for Crohn's disease in the United States. This is an important fact that many commercial stem cell clinics obscure or ignore.

Darvadstrocel (also known as Cx601), an adipose-derived mesenchymal stem cell product, is the only stem cell therapy approved anywhere in the world specifically for Crohn's-related perianal fistulas. It is available in the European Union, Israel, and Japan (4). Darvadstrocel consists of allogeneic (donor-derived) stem cells from fat tissue, which are expanded in a laboratory and then injected directly into the fistula tract.

For patients in the U.S. and other countries where darvadstrocel is not available, clinical trials remain the primary pathway to access stem cell treatments within a regulated, monitored setting.

How to Find Clinical Trials

Multiple clinical trials for stem cell therapy in Crohn's disease are ongoing at major medical centers including Mount Sinai, Penn State, and UC Davis. Patients interested in exploring this option should start by discussing eligibility with their gastroenterologist, who can help identify appropriate trials and assess whether the patient's disease characteristics match the trial criteria.

Clinical trial registries such as ClinicalTrials.gov allow patients to search for active studies by condition and location. It is worth remembering that trial participation includes close monitoring and follow-up, which many patients find beneficial beyond the experimental treatment itself.

Risks, Side Effects, and What to Watch Out For

The risk profile of stem cell therapy varies dramatically depending on the type of treatment, and patients need clear information to make informed decisions.

Known Risks of Stem Cell Treatment

For MSC injection targeting perianal fistulas, the safety profile is reassuring. Across multiple trials, adverse event rates were comparable to placebo, with the most common issues being local injection-site reactions, mild infections, and temporary pain (1). This favorable safety profile is one reason MSC therapy for fistulas has gained regulatory approval in several countries.

HSCT carries substantially higher risks. The conditioning chemotherapy suppresses the immune system, leaving patients vulnerable to serious infections during the recovery period. Depending on the protocol used, risks can include organ damage, prolonged hospitalization, and in rare cases, treatment-related mortality (5). The ASTIClite trial outcomes serve as a sobering reminder that even well-designed studies can encounter severe complications.

The risk-benefit calculation for HSCT is personal and depends heavily on how severe and treatment-resistant a patient's Crohn's disease is. For someone who has exhausted other options and faces ongoing suffering or repeated surgeries, the risks of HSCT may be acceptable - but this decision should be made in close consultation with experienced specialists.

Avoiding Unproven Stem Cell Clinics

This is perhaps the most important practical warning in this article. The growing interest in stem cell therapy has fueled a market of commercial clinics that offer unproven stem cell treatments directly to patients, often at costs of tens of thousands of dollars.

The FDA has repeatedly warned against unapproved stem cell products marketed to consumers. These clinics may use cell types that have not been studied for Crohn's disease, deliver them through unvalidated methods, and operate outside the safety oversight that clinical trials provide. Reports of serious harm from unregulated stem cell procedures - including infections, tumor formation, and worsened disease - underscore why this matters.

If a clinic is offering stem cell therapy for Crohn's disease outside of a registered clinical trial, and especially if they are charging substantial fees, that is a significant red flag. Legitimate stem cell research for Crohn's takes place at academic medical centers and is funded through research grants, not patient payments.

The Future of Stem Cell Research for Crohn's

The field is advancing on several fronts that could expand the role of stem cells in Crohn's disease management over the coming years.

Researchers are developing organoid "mini-guts" grown from patient stem cells - three-dimensional tissue models that mimic the intestinal lining. These organoids allow scientists to study fibrosis and test treatments in tissue that genetically matches the individual patient, opening the door to truly personalized therapy. This work is also being explored alongside other experimental approaches like fecal microbiota transplant.

Newer conditioning protocols are being developed to improve the safety of HSCT, learning from the lessons of the ASTIClite trial. The goal is to find a regimen intense enough to achieve a meaningful immune reset while minimizing the risk of serious complications.

Combination approaches - pairing stem cells with other therapies - are under investigation, and international registries are being established to track long-term outcomes from both MSC and HSCT procedures. These registries will be essential for understanding how durable the benefits of stem cell therapy truly are, and for identifying which patient populations benefit most.

Frequently Asked Questions

Is stem cell therapy approved for Crohn's disease?

In the United States, no stem cell therapy is FDA-approved for Crohn's disease. Darvadstrocel, an MSC-based product for perianal fistulas, is approved in the EU, Israel, and Japan (4). All other stem cell treatments for Crohn's remain experimental and should only be accessed through registered clinical trials.

How effective is stem cell therapy for perianal fistulas?

A meta-analysis of 12 randomized trials with 632 patients found MSC therapy more than doubled the odds of fistula remission compared to placebo, with a safety profile similar to placebo (1). Results vary between studies, and not all patients respond, but the overall evidence is encouraging for this specific application.

Who is a candidate for hematopoietic stem cell transplant?

HSCT is currently studied only for patients with severe Crohn's disease who have not responded to multiple biologic therapies and face ongoing symptoms or repeated surgeries. It is not appropriate for mild or moderate disease (2). Candidates are carefully screened at specialized transplant centers.

What are the risks of stem cell transplant for Crohn's?

MSC injection for fistulas has a favorable safety profile comparable to placebo. HSCT carries more significant risks including serious infection, organ damage, and in rare cases death, depending on the conditioning chemotherapy used (5). The choice of transplant protocol significantly influences the risk level.

How do I find a stem cell clinical trial for Crohn's disease?

Start by discussing your interest with your gastroenterologist, who can assess whether your disease characteristics match any active trial criteria. You can also search ClinicalTrials.gov by condition and location. Major centers with ongoing stem cell research for Crohn's include Mount Sinai, Penn State, and UC Davis.

Should I be worried about stem cell clinics advertising online?

Yes, caution is warranted. The FDA has warned against unregulated clinics offering unproven stem cell products at high cost. Legitimate stem cell research for Crohn's takes place at academic medical centers within registered clinical trials. If a clinic charges thousands of dollars for stem cell treatment outside a trial, that is a red flag.

How long does it take to see results from stem cell therapy?

For MSC injection targeting fistulas, clinical trials typically assess outcomes at 12 to 24 weeks after treatment. For HSCT, immune reconstitution takes several months, and full assessment of remission is usually done at 12 months or later (2). Response timelines vary by individual and treatment type.

References

1. Wang, Y., et al. Efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysis of randomized controlled trials. Stem Cell Research & Therapy, 2024. Read study
2. International Stem Cell Transplant Consortium. Efficacy and safety of autologous hematopoietic stem cell transplantation in refractory Crohn's disease: outcomes from the international stem cell transplant consortium. Journal of Crohn's and Colitis, 2025. Read study
3. UC Davis Health. UC Davis Health leads study on promising stem cell-based therapy for Crohn's disease. 2024. Read article
4. MyCrohnsAndColitisTeam. Stem Cell Therapy for Crohn's Disease: 5 Facts To Know. 2025. Read article
5. Hawkey, C.J., et al. Safety and efficacy of autologous haematopoietic stem-cell transplantation in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial. The Lancet, 2024. Read study